Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 989-996 , November 2010

Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists

  • Rama Pichika

      Affiliations

    • Department of Radiology, University of California, San Diego, CA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 858 373 2860; fax: +1 858 373 2865.
    • ,
  • Douglas M. Jewett

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Philip S. Sherman

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • John R. Traynor

      Affiliations

    • Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Stephen M. Husbands

      Affiliations

    • Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
    • ,
  • James H. Woods

      Affiliations

    • Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Michael R. Kilbourn

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Received 21 April 2010 ,Revised 20 May 2010 ,Accepted 1 June 2010.

References 

  1. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. μ-, δ- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res. 2001;893:121–134
  2. Fraser GL, Gaudreau GA, Clarke PBS, Menard DP, Perkins MN. Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammation. Br J Pharmacol. 2000;129:1668–1672
  3. Negus SS, Butelman ER, Chang KJ, DeCosta B, Winger G, Woods JH. Behavioral effects of the systemically active δ opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther. 1994;270:1025–1034
  4. Lever JR, Scheffel U, Kinter CM, Ravert HT, Dannals RF, Wagner HN, et al. In vivo binding of N1′-([11C]methyl)naltrindole to δ-opioid receptors in mouse brain. Eur J Pharmacol. 1992;216:459–460
  5. Hepburn MJ, Little PJ, Gingras J, Kuhn CM. Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. J Pharmacol Exp Ther. 1997;281:1350–1356
  6. Shippenberg TS, Heidbreder C. The δ-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine. Eur J Pharmacol. 1995;280:55–61
  7. Gaveriaux-Ruff C, Filliol D, Simonin F, Matthes HW, Kieffer BL. Immunosuppression by δ-opioid antagonist naltrindole: δ- and triple μ/δ/κ-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther. 2001;298:1193–1198
  8. House RV, Thomas PT, Kozak JT, Bhargava HN. Suppression of immune function by non-peptidic δ opioid receptor antagonists. Neurosci Lett. 1995;198:119–122
  9. Campa MJ, Schreiber G, Bepler G, Bishop MJ, McNutt RW, Chang KJ, et al. Characterization of δ opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. 1996;56:1695–1701
  10. Frost JJ. PET imaging of the opioid receptor: the early years. Nucl Med Biol. 2001;28:509–513
  11. Koepp MJ, Duncan JS. PET: Opiate neuroreceptor mapping. Adv in Neurol. 2000;83:145–156
  12. Madar I, Lever JR, Kinter CM, Scheffel U, Ravert HT, Musachio JL, et al. Imaging of δ opioid receptors in human brain by N1′-([11C]methyl)naltrindole and PET. Synapse. 1996;24:19–28
  13. Smith JS, Zubieta JK, Price JC, Flesher JE, Madar I, Lever JR, et al. Quantification of δ-opioid receptors in human brain with N1′-([11C]methyl)naltrindole and positron emission tomography. J Cer Blood Flow Metab. 1999;19:956–966
  14. Tyacke RJ, Robinson ESJ, Schnabel R, Lewis JW, Husbands SM, Nutt DJ, et al. N1′-fluoroethyl-naltrindole (BU97001) and N1′-fluoroethyl-(14-formylamino)-naltrindole (BU97018) potential δ-opioid receptor PET ligands. Nucl Med Biol. 2002;29:455–462
  15. Calderon SN, Rice KC, Rothman RB, Porreca F, Flippen-Anderson JL, Kayakiri H, et al. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective δ-agonist (+)-4-[(αR)-α-((2S, 5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80) and related novel nonpeptide δ opioid receptor ligands. J Med Chem. 1997;40:695–704
  16. Podlogar BL, Poda GI, Demeter DA, Zhang SP, Carson JR, Neilson A, et al. Synthesis and evaluation of 4-(N,N-diarylamino)piperidines with high selectivity to the δ-opioid receptor: a combined 3D-QSAR and ligand docking study. Drug Design Disco. 2000;17:34–50
  17. Wei ZY, Brown W, Takasaki B, Plobeck N, Delorme D, Zhou F, et al. N,N-diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent δ opioid receptor agonist with oral bioavailability and its analogues. J Med Chem. 2000;43:3895–3905
  18. Zhang X, Rice KC, Calderon SN, Kayakiri H, Smith L, Coop A, et al. Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic δ opioid receptor ligands. J Med Chem. 1999;42:5455–5463
  19. Jewett DM. A simple synthesis of [11C]methyl triflate. Appl Radiat Isot. 1992;43:1383–1385
  20. Bormans G, Sherman P, Snyder SE, Kilbourn MR. Synthesis of carbon-11 and fluorine-18 labeled 1-methyl-4-piperidyl-4-fluorobenzoate and their biodistribution in mice. Nucl Med Biol. 1996;23:513–517
  21. Charalambous A, Mangner TJ, Kilbourn MR. Synthesis of (2-[11C] Methoxy) rotenone, a marker of mitochondrial complex I activity. Nucl Med Biol. 1995;22:65–69
  22. Schetz JA, Calderon SN, Bertha CM, Rice K, Porreca F. Rapid in vivo metabolism of a methylether derivative of (±)-BW373U86: the metabolic fate of [3H]SNC121 in rats. J Pharmacol Exp Ther. 1996;279:1069–1076
  23. Dagenais C, Ducharme J, Pollack GM. Interaction of nonpeptidic δ agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy. J Pharm Sci. 2002;91:244–252
  24. Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Disp. 1999;27:827–834
  25. Thompson SJ, Koszdin K, Bernards CM. Does P-glycoprotein limit opioid-induced analgesia in vivo?. Anesthesiology. 2000;92:1392–1399
  26. Zong J, Pollack GM. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharmeutical Res. 2000;17:749–753

☆ Presented this work at the 222nd American Chemical Society National Meeting, Chicago, IL August 26-30, 2001.

PII: S0969-8051(10)00307-0

doi: 10.1016/j.nucmedbio.2010.06.002

Nuclear Medicine and Biology
Volume 37, Issue 8 , Pages 989-996 , November 2010

Article Tools

* Image Usage & Resolution